Patents Issued in November 20, 2018
  • Patent number: 10130557
    Abstract: A child-resistant blister package. The package has a top face, a bottom face, and a periphery. The package also has a protection layer with a top face, a bottom face and a periphery; a blister layer with one or more cavities; and an access layer with a top face, a bottom face, and a periphery. The bottom face of the access layer has a line of weakness that allows the unit dose to be removed from the cavity in one-step by applying a force to the top of the cavity and pressing the unit dose through the line of weakness. The bottom face of the protection layer and the top face of the access layer are permanently joined along substantially the entire periphery of the package. The blister package can also contain a tear resistant layer.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 20, 2018
    Assignee: The Procter & Gamble Company
    Inventors: Kurt Franklin Trombley, Karen Lai-Ting Chan, Isabelle Lafosse-Marin, Jay Robert Morosey, Jr., Karla Mishell Sanchez, Kelly Lee Schmeichel
  • Patent number: 10130558
    Abstract: A coded collapsible drug reservoir and a drug delivery system including the coded collapsible drug reservoir. The drug reservoir includes a collapsible housing and a port in communication with the collapsible housing. The drug reservoir further includes a coding feature disposed on the drug reservoir, and the coding feature identifies the drug reservoir.
    Type: Grant
    Filed: January 21, 2011
    Date of Patent: November 20, 2018
    Assignee: Sanofi-Aventis Deutschland GmbH
    Inventor: Richard James Vincent Avery
  • Patent number: 10130559
    Abstract: A stoma dilation device that includes a tubular support and an inflatable dilation portion located on the tubular support. The inflatable dilation portion includes a stiffening portion and inflation lumen. The device may have a retention portion configured to have a diameter upon full, unrestrained inflation that is greater than the diameter of the dilation portion. The device is designed to be placed in a patient to dilate the stoma for the installation of a catheter feeding tube. The device may be placed and withdrawn with the use of an endoscope which need be inserted into the patient only one time. The single insertion of the endoscope significantly reduces the trauma to the patient in comparison with multiple endoscope insertion methods.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: November 20, 2018
    Assignee: Avent, Inc.
    Inventor: Kok-Ming Tai
  • Patent number: 10130560
    Abstract: Provided herein are composite materials comprising a thiol-ene polymer resin in a continuous phase and a filler in a discontinuous phase, the filler comprising fluorapatite crystals and silica. Further provided are methods of using these composite materials as restoratives in dental applications. This dental composite is labeled as “smart” because, when the shrinkage stress of the composite is greater than a programmable or pre-selected threshold level, it will elicit visual clues for the dentist.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: November 20, 2018
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Brian H. Clarkson, Timothy F. Scott
  • Patent number: 10130561
    Abstract: A method for repairing dentition, including milling beta tricalcium phosphate with sufficiently high energy to substantially distressed its lattice structure, mechanochemically chelating an edible acid thereto to yield functionalized calcium phosphate moieties, and incorporating the functionalized calcium phosphate moieties into an edible material to yield a calcium phosphate delivery system. The calcium phosphate delivery system is introduced into an oral environment and dentition is repaired. The functionalized calcium phosphate moiety is characterized by weakly bonded fumaric acid at least partially wrapped around distressed calcium phosphate particles, and dentition repair occurs at a dentition depth of at least 10 microns below the surface.
    Type: Grant
    Filed: July 23, 2009
    Date of Patent: November 20, 2018
    Inventor: Robert L. Karlinsey
  • Patent number: 10130562
    Abstract: Monomer mixture for the preparation of dental materials, which contains at least one low-volatile monomethacrylate, at least one highly viscous polyfunctional methacrylate and at least one low-viscosity polyfunctional methacrylate.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: November 20, 2018
    Assignee: Ivoclar Vivadent AG
    Inventors: Norbert Moszner, Peter Burtscher, Alexandros Gianasmidis
  • Patent number: 10130563
    Abstract: Provided are dental polymerizable monomer compositions that can give cured products having high toughness and high rigidity, and dental compositions containing such dental polymerizable monomer compositions and cured products thereof having high mechanical properties.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: November 20, 2018
    Assignees: MITSUI CHEMICALS, INC., SHOFU INC., SUN MEDICAL CO., LTD.
    Inventors: Kazuhiko Yoshinaga, Hiroshi Naruse, Mitsuji Teramae, Kiyomi Fuchigami, Hidefumi Fujimura, Masuji Tsuchikawa, Hirofumi Imai
  • Patent number: 10130564
    Abstract: Provided are dental polymerizable monomers that can give cured products having high toughness and high rigidity, dental polymerizable monomer compositions containing the polymerizable monomers, and dental compositions containing the dental polymerizable monomer compositions, and cured products thereof having high mechanical properties. The dental polymerizable monomer (A) which includes a urethane acrylate obtained from an appropriately rigid diisocyanate and an appropriately flexible hydroxyacrylate is used to prepare a dental polymerizable monomer composition containing the dental polymerizable monomer, and a dental composition containing the dental polymerizable monomer composition.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: November 20, 2018
    Assignees: MITSUI CHEMICALS, INC., SHOFU INC., SUN MEDICAL CO., LTD.
    Inventors: Kazuhiko Yoshinaga, Hiroshi Naruse, Mitsuji Teramae, Kiyomi Fuchigami, Hidefumi Fujimura, Masuji Tsuchikawa, Hirofumi Imai
  • Patent number: 10130565
    Abstract: The present invention relates to a solid cosmetic composition in the form of a compact powder, comprising, in a physiologically acceptable medium, at least: —a pulverulent phase in an amount of greater than or equal to 35% by weight relative to the total weight of the composition, —a liquid fatty phase comprising at least one non-volatile oil, and —at least one amorphous hydrocarbon-based block copolymer. The present invention also relates to a process for coating the face, and in particular the eyelids, with the said cosmetic composition.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: November 20, 2018
    Assignee: L'OREAL
    Inventors: Padraig Mac Dermott, Mickael Bailleul, Gwenola Le Gars
  • Patent number: 10130566
    Abstract: The object is the invention is to provide hollow, and preferably porous, spherical CaP particles preferably without the use of strontium ions. This is achieved by a method comprising the steps: a) Providing an aqueous buffer solution of purified water having a pH of 6-10 comprising 20-200 mM sodium ions, 0.1-10 mM potassium ions and 1-10 mM phosphate ions, and wherein the buffer solution is essentially free from strontium; b) adding calcium ions in the range of from 0.1 to less than 2 mM, and magnesium ions in the range of 0.01-5 mM to the buffer solution and forming a mixture; c) heating the mixture of step b) at 60-200° C. for at least 5 minutes d) isolating the formed particles; and e) optionally washing the isolated particles using a suitable solvent. The particles comprise 40-70 weight % of calcium, 20-40 weight % of phosphate and 1-25 weight % magnesium. The Ca/P weight ratio is in the range of 1.10 to 1.90 and more than 80 % of the particles have a particle size between 200 to 1500 nm.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: November 20, 2018
    Assignee: PSILOX AB
    Inventors: Wei Xia, Håkan Engqvist
  • Patent number: 10130567
    Abstract: The present invention is directed to an oral composition containing a gel network phase comprising: (i) one or more fatty amphiphiles, (ii) one or more surfactants, and (iii) one or more solvents; and an oral carrier phase. In certain embodiments, the gel network is used to structure the oral composition. The present invention is also directed to a method of forming an oral composition containing a gel network.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: November 20, 2018
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: George Endel Deckner, Arif Ali Baig, Michael Jude LeBlanc
  • Patent number: 10130568
    Abstract: The present invention relates to a process for dyeing or lightening keratin fibres, comprising the step of extemporaneously mixing at the time of use two compositions (A) and (B) and of applying the said mixture to the said fibres; the said mixture comprising at least 25% by weight of fatty substances relative to the total weight of the composition obtained from the mixing of two compositions (A)+(B); with: —(A) representing a composition in direct emulsion form whose content of oil(s) ii) is at least 30% by weight relative to the weight of composition (A), and comprising: i) at least one nonionic surfactant that is solid at room temperature and at atmospheric pressure, with an HLB ranging from 1.5 to 10; ii) at least one basifying agent; Hi) optionally at least one additional surfactant other than the solid nonionic surfactants (i), iv) optionally at least one dye; and—(B) representing a composition comprising at least one chemical oxidizing agent.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: November 20, 2018
    Assignee: L'OREAL
    Inventors: Philippe Rapold, Gautier Deconinck, Caroline Goget, Luc Nicolas-Morgantini, Frédéric Simonet, Sophie Bouxirot
  • Patent number: 10130569
    Abstract: Dentifrice compositions with high water, a calcium-containing abrasive, an alkaline pH and minimal or nil amounts of polyols, such as PEG humectants, provide improved anti-plaque benefits.
    Type: Grant
    Filed: March 2, 2015
    Date of Patent: November 20, 2018
    Assignee: THE PROCTER & GAMBLE COMPANY
    Inventors: Haijing Chen, Ross Strand, Donald James White, Jr., Hongmei Yang
  • Patent number: 10130570
    Abstract: A cosmetic product includes a) a cosmetic preparation including, in relation to the total weight of the preparation, a1) 60 to 94 wt % polar solvent; a2) 0.1 to 20 wt % oxidant; and b) a device for flash-evaporating the cosmetic preparation a). A method for changing the color of keratinous fibers incorporates such a product. Particularly, the cosmetic preparation a) is used as a process material in a flash evaporation device.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: November 20, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Burkhard Mueller, Thorsten Knappe
  • Patent number: 10130571
    Abstract: Disclosed herein are dentifrices comprising a zinc amino acid complex together with soluble phosphate salts. Methods of making and using the dentifrices are also provided.
    Type: Grant
    Filed: June 18, 2014
    Date of Patent: November 20, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Gregory Szewczyk, Lisa Manus, Lyndsay Schaeffer-Korbylo
  • Patent number: 10130572
    Abstract: A method for concealing vitiligo is provided. The method comprises depressing a spring head. The spring head may be covered by a covering. Depression of the spring head may saturate the covering with a solution. The solution may include a bronzer and dihydroxyacetone (“DHA”). The method may also comprise guiding the saturated covering over a portion of depigmented skin.
    Type: Grant
    Filed: April 12, 2018
    Date of Patent: November 20, 2018
    Assignee: Zanderm LLC
    Inventors: James R. Adelson, Sara R. Frankel
  • Patent number: 10130573
    Abstract: The present invention is a composition and method of treatment for skin disorders, conditions, and severe skin dryness in general through topical systematic and periodic application of a formulation that generally may include salicylic acid, glycolic acid, urea, dimethyl isosorbide, ethoxydiglycol, barrier repair agents, anti-irritants, humectants, and also has an acidic pH formulation.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 20, 2018
    Assignee: Clark Pharmaceuticals LLC
    Inventors: Stephen W. Clark, Natalie Barger
  • Patent number: 10130574
    Abstract: Provided are compositions useful for inhibiting oxidation of unsaturated fats comprising an antioxidant compound of Formula I: wherein R, R1, R2, R3, R4, R5 and R6 are as defined herein.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: November 20, 2018
    Assignees: Dow Global Technologies LLC, Rohm and Haas Company
    Inventors: Cassie Fhaner, Kinjalbahen Joshi, Yujing Tan
  • Patent number: 10130575
    Abstract: The present invention relates to a composition for dyeing keratin fibers, in particular human keratin fibers such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof or solvates thereof such as hydrates; b) at least one coupler; c) at least 10% by weight of the total weight of the composition of a fatty substance which is preferably liquid and non-silicone-based; d) at least one amphoteric surfactant; e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibers such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: November 20, 2018
    Assignee: L'OREAL
    Inventors: Valerie Nicou, Isabelle Rollat
  • Patent number: 10130576
    Abstract: The present invention relates to oral compositions, comprising select phospholipid surfactants. Methods for using the compositions are also disclosed.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: November 20, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Patricia L. Golas, Carolyn J. Mordas
  • Patent number: 10130577
    Abstract: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: November 20, 2018
    Assignee: The Procter & Gamble Company
    Inventor: Rosemarie Osborne
  • Patent number: 10130578
    Abstract: Low pH compositions for topical administration to skin are provided. They comprise a buffering agent having a pKa of about 2.8 to about 4.2 and a cosmetically acceptable active ingredient having a pKa within about 1 unit of the pKa of the buffering agent. The composition has a pH of about 3.3 to 4 and a buffer capacity of at least about 0.15. A method of increasing the topical delivery of a cosmetically acceptable active ingredient having a pKa of about 2.8 to about 4 is also provided.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: November 20, 2018
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Anne-Sophie Brillouet, Marisa DeVita Dufort, Ali Fassih, Devin L. Garcia, Ya-Ping Hu, Wen-Hwa Ting Li, Ramine Parsa, Jyotsna Paturi, Dianne Rossetti, Ying Sun, Janet Wangari-Talbot, Robert Wayne Yates
  • Patent number: 10130579
    Abstract: A cosmetic material comprises (A) a hydrophobic powder; (B) a carboxylic acid modified silicone; (C) a basic compound; and (D) water. The (A) hydrophobic powder is generally dispersed in an aqueous phase of the cosmetic material. The cosmetic material can provide a refreshing sense of feel during use, and can form a cosmetic film with excellent water resistance on the skin.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: November 20, 2018
    Assignee: DOW CORNING TORAY CO., LTD.
    Inventors: Yuichi Kanaya, Jun Miyano, Akihiro Nakano, Yusuke Narita
  • Patent number: 10130580
    Abstract: There is provided a method for preparing an orally disintegrating tablet (ODT) composition comprising microparticles of one or more taste-masked active pharmaceutical ingredient(s), rapidly-dispersing microgranules, and other optional, pharmaceutically acceptable excipients wherein the ODT disintegrates on contact with saliva in the buccal cavity in about 60 seconds forming a smooth, easy-to-swallow suspension. Furthermore, the microparticles (crystals, granules, beads or pellets containing the active) applied with a taste-masking membrane comprising a combination of water-insoluble and gastrosoluble polymers release not less than about 60% of the dose is in the stomach in about 30 minutes, thus maximizing the probability of achieving bioequivalence to the reference IR product having rapid onset of action (short Tmax). A process for preparing such compositions for oral administration using conventional fluid-bed equipment and rotary tablet press is also disclosed.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 20, 2018
    Assignee: ADARE PHARMACEUTICALS, INC.
    Inventor: Gopi M. Venkatesh
  • Patent number: 10130581
    Abstract: Methods are provided for drying a particle. Specifically, there is provided a spray-dried diketopiperazine-insulin particle formulation having improved aerodynamic performance and in which the active agent is more stabile and efficiently delivered as compared to that of the lyophilized diketopiperazine-insulin formulation. The dry powders have utility as pharmaceutical formulations for pulmonary delivery.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 20, 2018
    Assignee: MannKind Corporation
    Inventors: Bryan R. Wilson, Marshall Grant
  • Patent number: 10130582
    Abstract: The present disclosure relates to pharmaceutically acceptable complex formulae comprising complexes of Abiraterone acetate and pharmaceutically acceptable excipients, process for the preparation thereof and pharmaceutical compositions containing them. The complex formulae of the present disclosure have improved physicochemical properties which results in reduced food effect which allows significant dose reduction and the abandoning of the requirement of taking the drug on an empty stomach.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: November 20, 2018
    Assignee: Druggability Technologies IP Holdco Limited
    Inventors: Réka Angi, Tamás Jordán, Orsolya Basa-Dénes, Tamás Solymosi, Zsolt Ötvös, Hristos Glavinas, Genovéva Filipcsei
  • Patent number: 10130583
    Abstract: The invention relates to a new powder composition which comprises in admixture: lactic acid, lactose and kaolin, wherein the amount of lactic acid is such that the pH of the powder composition should be within the range of about 3 to 4. Said powder composition may be use as a veterinary drug and in treating and/or preventing a disorder in the auditory canal of dogs and cats.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: November 20, 2018
    Assignee: Pegion Operations Limited
    Inventor: Claes Thulin
  • Patent number: 10130584
    Abstract: The purpose of the present invention is to provide a new disintegrative particulate composition having an optimal balance between the tablet hardness and disintegrability that are mutually opposing properties, and disintegrating tablets for pharmaceuticals and various kinds of foods comprising said composition. The present invention relates to a disintegrative particulate composition comprising milled lactose and/or granulated lactose as an excipient, and to a disintegrating tablet for pharmaceuticals or foods, comprising the disintegrative particulate composition, especially the tablet having tablet hardness of from 20 to 200 N, and disintegration time in water of from 1 to 60 sec.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: November 20, 2018
    Assignee: DAICEL CORPORATION
    Inventors: Takahiro Hiramura, Kiyoshi Ikura, Tomohito Okabayashi, Yoshihisa Takigawa, Naohiro Hashikawa
  • Patent number: 10130585
    Abstract: Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are provided.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: November 20, 2018
    Assignee: Murray and Poole Enterprises Limited
    Inventor: Susanne Riel
  • Patent number: 10130586
    Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: November 20, 2018
    Assignees: Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P.
    Inventors: Curtis Wright, Benjamin Oshlack, Christopher Breder
  • Patent number: 10130587
    Abstract: The present disclosure concerns embodiments of new hard pullulan capsule shells and capsules comprising (I) moisture, (II) a mono-, di-, and oligosaccharides free pullulan and (III) a setting system. Also provided are an aqueous composition and a dip-molding manufacturing method for the manufacture of such shells and capsules.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: November 20, 2018
    Assignee: Capsugel Belgium NV
    Inventors: Dominique Nicolas Cade, Takahisa Takubo
  • Patent number: 10130588
    Abstract: The present invention is related to silicon nanoparticles, a pharmaceutical composition comprising silicon nanoparticles, a method for synthesis of the silicon nanoparticles and their use for in vivo diagnostics, visualization of drug delivery or staining of cells, biological processes or pathways. The silicon nanoparticles are characterized that they comprise a silicon core of a size of 1 to 10 nm and are terminated with allylamine or poly(allylamine) comprising up to 10 allylamine groups.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: November 20, 2018
    Assignee: WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER
    Inventors: Holger Stephan, Ralf Bergmann, Alexander Ruffani, Luisa DeCola
  • Patent number: 10130589
    Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: November 20, 2018
    Assignees: UCB Pharma GmbH, LTS Lohmann Therapie-Systeme AG
    Inventors: Hans-Michael Wolff, Christoph Arth, Luc Quere, Walter Müller
  • Patent number: 10130590
    Abstract: Described herein are, inter alia, methods for decreasing the growth of a cancer cell, the method comprising delivering to a target cancer cell a growth-inhibitory amount of an atovaquone-related compound, wherein, prior to the delivery, an increased level of activation of the mTOR pathway in the cancer compared to a control level of activation of the mTOR pathway has been found. Also provided are methods for determining the susceptibility of cancer to treatment with an atovaquone-related compound and for assessing the success of therapy with such a compound.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: November 20, 2018
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: David Frank, Michael Xiang
  • Patent number: 10130591
    Abstract: The present invention relates to an abuse-proofed, thermoformed dosage form containing, in addition to one or more active ingredients with abuse potential optionally together with physiologically acceptable auxiliary substances, at least one synthetic or natural polymer with a breaking strength of at least 500 N and to a process for the production thereof.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: November 20, 2018
    Assignee: GRÜNENTHAL GMBH
    Inventors: Johannes Bartholomäus, Heinrich Kugelmann, Elisabeth Arkenau-Marić
  • Patent number: 10130592
    Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
    Type: Grant
    Filed: September 23, 2015
    Date of Patent: November 20, 2018
    Assignee: PAR PHARMACEUTICAL, INC.
    Inventors: Vinayagam Kannan, Patrick Irish, Michael Bergren
  • Patent number: 10130593
    Abstract: This disclosure concerns the discovery of the use of fenoterol analogs for regulating cannabinoid (CB) receptor activity-related disorders and disease, such as dysregulated CB receptors, including treating a disorder or disease, such as a glioblastoma, hepatocellular carcinoma, liver cancer, colon cancer, and/or lung cancer, which is associated with altered cannabinoid receptor activity. In one example, the method includes administering to a subject having or at risk of developing a disorder or disease regulated by CB receptor activity an effective amount of a fenoterol analog to reduce one or more symptoms associated with the disorder or disease regulated by CB receptor activity.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: November 20, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Irving William Wainer, Michel Bernier, Rajib Kumar Paul
  • Patent number: 10130594
    Abstract: This disclosure concerns the discovery of the use of fenoterol and (R,R)- and (R,S)-fenoterol analogs for the treatment of a tumor expressing a ?2-adrenergic receptor, such as a primary brain tumor, including a glioblastoma or astrocytoma expressing a ?2-adrenergic receptor. In one example, the method includes administering to a subject a therapeutically effective amount of fenoterol, a specific fenoterol analog or a combination thereof to reduce one or more symptoms associated with the tumor, thereby treating the tumor in the subject.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: November 20, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, SRI International
    Inventors: Irving W. Wainer, Michel Bernier, Lawrence Robert Toll, Lucita Arenas Jimenez
  • Patent number: 10130595
    Abstract: A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: November 20, 2018
    Assignees: CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, David Grierson, Florence Mahuteau-Betzer, Pierre Roux
  • Patent number: 10130596
    Abstract: Pharmaceutical compositions for reducing frequency of urination are disclosed. The pharmaceutical compositions comprise one or more prostaglandin pathway inhibitors and a pharmaceutically acceptable carrier. Also disclosed are methods of making and using the pharmaceutical compositions.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: November 20, 2018
    Assignee: WELLESLEY PHARMACEUTICALS, LLC
    Inventor: David A. Dill
  • Patent number: 10130597
    Abstract: The present invention provides oral instruments comprising a basic amino acid, to compositions for making such instruments, and to methods of making and using such instruments.
    Type: Grant
    Filed: February 6, 2009
    Date of Patent: November 20, 2018
    Assignee: Colgate-Palmolive Company
    Inventors: Michael Prencipe, Richard Scott Robinson, Rajnish Kohli, Richard J. Sullivan, Diane Cummins
  • Patent number: 10130598
    Abstract: The present disclosure relates to the discovery that compounds of the invention, particularly 3-bromopyruvate and related compounds, can be safely administered at concentrations effective for the treatment of cancer when formulated with an acidity of greater than or equal to pH of 2 and less than or equal to a pH of 6. Disclosed herein are novel and improved methods and compositions for the treatment of cancer using 3-halopyruvate and related compounds.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 20, 2018
    Assignee: The Johns Hopkins University
    Inventors: Jean-Francois Geschwind, Mustafa Vali
  • Patent number: 10130599
    Abstract: A mineral-vitamin complex for osteoporosis includes at least 92 mass % of the mineral-vitamin complex of amino acids and Krebs cycle acids and/or Krebs cycle acid salts, wherein the amino acids include glycine of between 1% and 80% of the mineral-vitamin complex, and wherein the Krebs cycle acids and/or Krebs cycle acid salts are up to 5 mass % of the mineral-vitamin complex; and valine, leucine and isoleucine such that a mass ratio of glycine to a sum of valine+leucine+isoleucine is in a range of 10-1000. Optionally, the valine, leucine and isoleucine are derived from dry milk, any stable dry product derived from milk and/or a mix thereof. Optionally, the following compounds are used as a source of Krebs cycle acid salts: Y-Me-Y.nH2O, where Me—divalent metal, from Ca, Mg, Zn group, Y—anion of an acid participating in Krebs cycle, and n=0-12.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: November 20, 2018
    Inventors: Mikhail Lvovich Uchitel, Roman Anatolievich Trunin, Evgenij Iljich Maevskij
  • Patent number: 10130600
    Abstract: Methods and compositions for treating Ras-related cancers are provided that involve targeting lipid scavenging. Methods and compositions for identifying and/or characterizing more or less responsive cancers are also provided.
    Type: Grant
    Filed: May 9, 2014
    Date of Patent: November 20, 2018
    Assignees: Memorial Sloan Kettering Cancer Center, The Trustees of Princeton University
    Inventors: Joshua Rabinowitz, Jurre Kamphorst, Craig Thompson, Justin Cross
  • Patent number: 10130601
    Abstract: The present invention provides use of a composition comprising fish oil with low totox value and juice in an oil-in-water emulsion in treatment/resolution of inflammation and/or diseases wherein an underlying cause is inflammation. The invention encompasses further said composition comprising acetylsalicylic acid and/or derivatives and/or analogous thereof. Further the present invention is related to the combined use of a composition of the invention and a therapeutic agent for the treatment of inflammatory diseases or diseases wherein an underlying cause is inflammation.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: November 20, 2018
    Assignee: Smartfish AS
    Inventor: Janne Sande Mathisen
  • Patent number: 10130602
    Abstract: The invention relates to the use of L-carnitine, a salt of L-carnitine, a derivative of L-carnitine and/or salt of a derivative of L-carnitine, as well as respective methods and compositions, for reducing or preventing fatigue and/or for improving cognitive function in an animal. The animal is preferably a healthy individual and the use is preferably a non-therapeutic use.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: November 20, 2018
    Assignee: Lonza Ltd.
    Inventors: Adriana Williams, Frauke Warrikoff, Ulla Freitas, Richard Sasse, Kevin Owen
  • Patent number: 10130603
    Abstract: Provided are methods and compositions for improving kidney function and for the treatment or prophylaxis of kidney disease in dogs.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: November 20, 2018
    Assignee: Colgate-Palmolive Company
    Inventor: Dennis Jewell
  • Patent number: 10130604
    Abstract: The present invention provides a method and composition for treating a neurodegenerative disease. In particular, the present invention provides a method and composition to increase DJ-1 gene expression or DJ-1 protein activity to treat a neurodegenerative disease.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: November 20, 2018
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventors: Curt R. Freed, Wenbo Zhou
  • Patent number: 10130605
    Abstract: Compositions for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis in a subject in need thereof are disclosed. The composition comprises a therapeutically effective amount of an anthraquinone derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle. In one embodiment, the composition comprises diacerein. Also disclosed is a first composition comprising an anthraquinone derivative selected from the group consisting of diacerein, aloe-emodin, emodin, and rhein, and a first pharmaceutically acceptable vehicle; and a second composition comprising mesalazine, and a second pharmaceutically acceptable vehicle, in combination for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 20, 2018
    Assignee: TAIRX, INC.
    Inventors: Yi-Wen Chu, Du-Shieng Chien
  • Patent number: 10130606
    Abstract: Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle are described as retinoid replacement therapies for treating retinal degenerations in humans.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: November 20, 2018
    Assignee: NOVELION THERAPEUTICS INC.
    Inventor: Ronald Erwin Boch